Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

34 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Bone-targeted therapy in metastatic breast cancer - all well-established knowledge?
Gampenrieder SP, Rinnerthaler G, Greil R. Gampenrieder SP, et al. Breast Care (Basel). 2014 Oct;9(5):323-30. doi: 10.1159/000368710. Breast Care (Basel). 2014. PMID: 25759612 Free PMC article. Review.
Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer.
Bartsch R, Wenzel C, Gampenrieder SP, Pluschnig U, Altorjai G, Rudas M, Mader RM, Dubsky P, Rottenfusser A, Gnant M, Zielinski CC, Steger GG. Bartsch R, et al. Cancer Chemother Pharmacol. 2008 Oct;62(5):903-10. doi: 10.1007/s00280-008-0682-1. Epub 2008 Feb 7. Cancer Chemother Pharmacol. 2008. PMID: 18256835
Capecitabine and Vinorelbine as an All-Oral Chemotherapy in HER2-Negative Locally Advanced and Metastatic Breast Cancer.
Gampenrieder SP, Bartsch R, Matzneller P, Pluschnig U, Dubsky P, Gnant MX, Zielinski CC, Steger GG. Gampenrieder SP, et al. Breast Care (Basel). 2010;5(3):158-162. doi: 10.1159/000314214. Epub 2010 May 27. Breast Care (Basel). 2010. PMID: 21048830 Free PMC article.
Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer?
Huemer F, Gampenrieder SP, Schlattau A, Greil R. Huemer F, et al. Clin Breast Cancer. 2014 Feb;14(1):e17-20. doi: 10.1016/j.clbc.2013.09.009. Epub 2013 Sep 28. Clin Breast Cancer. 2014. PMID: 24246725 No abstract available.
Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis.
Gampenrieder SP, Romeder F, Muß C, Pircher M, Ressler S, Rinnerthaler G, Bartsch R, Sattlberger C, Mlineritsch B, Greil R. Gampenrieder SP, et al. Anticancer Res. 2014 Jan;34(1):227-33. Anticancer Res. 2014. PMID: 24403467 Clinical Trial.
Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.
Pircher M, Mlineritsch B, Fridrik MA, Dittrich C, Lang A, Petru E, Weltermann A, Thaler J, Hufnagl C, Gampenrieder SP, Rinnerthaler G, Ressler S, Ulmer H, Greil R. Pircher M, et al. Anticancer Res. 2015 Jan;35(1):517-21. Anticancer Res. 2015. PMID: 25550597 Clinical Trial.
miR-16-5p Is a Stably-Expressed Housekeeping MicroRNA in Breast Cancer Tissues from Primary Tumors and from Metastatic Sites.
Rinnerthaler G, Hackl H, Gampenrieder SP, Hamacher F, Hufnagl C, Hauser-Kronberger C, Zehentmayr F, Fastner G, Sedlmayer F, Mlineritsch B, Greil R. Rinnerthaler G, et al. Int J Mol Sci. 2016 Jan 26;17(2):156. doi: 10.3390/ijms17020156. Int J Mol Sci. 2016. PMID: 26821018 Free PMC article.
Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.
Gampenrieder SP, Hufnagl C, Brechelmacher S, Huemer F, Hackl H, Rinnerthaler G, Romeder F, Monzo Fuentes C, Morre P, Hauser-Kronberger C, Mlineritsch B, Greil R. Gampenrieder SP, et al. Pharmacogenomics J. 2017 Jul;17(4):344-350. doi: 10.1038/tpj.2016.25. Epub 2016 May 3. Pharmacogenomics J. 2017. PMID: 27139155
CDK4/6 inhibition in luminal breast cancer.
Gampenrieder SP, Rinnerthaler G, Greil R. Gampenrieder SP, et al. Memo. 2016;9:76-81. doi: 10.1007/s12254-016-0268-2. Epub 2016 Jun 20. Memo. 2016. PMID: 27429659 Free PMC article. Review.
34 results
Jump to page